Clinical evidence has indicated that only these ‘immune hot’ tumors distinguished by elevated T cell infiltration, increased PD-L1 expression, a high tumor mutation burden (TMB), and enhanced interferon-γ (IFN-γ) signaling exhibit favorable responses to ICB therapy, the most prevalently applied immunotherapy in clinics [4,5]. Here, CD274 is linked to neoplasm.